

INFINITY PHARMACEUTICALS, INC.
 Form 3
 February 14, 2017

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Kutok Jeffery (Last) (First) (Middle) C/O INFINITY PHARMACEUTICALS, INC., 784 MEMORIAL DRIVE. (Street) CAMBRIDGE, MA 02139 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/10/2017	3. Issuer Name and Ticker or Trading Symbol INFINITY PHARMACEUTICALS, INC. [INFI]	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) Chief Scientific Officer	5. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
---	--	--	--	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,072.97	I	By 401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security	4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership
---	---	--	---------------------------	----------------------	--

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Stock Option (Right to Buy)	01/04/2011 ⁽¹⁾	01/04/2021	Common Stock	6,583	\$ 5.94	D	Â
Stock Option (Right to Buy)	01/06/2012 ⁽²⁾	01/06/2022	Common Stock	9,968	\$ 7.93	D	Â
Stock Option (Right to Buy)	Â ⁽²⁾	03/02/2022	Common Stock	4,300	\$ 8.12	D	Â
Stock Option (Right to Buy)	Â ⁽²⁾	01/04/2023	Common Stock	10,113	\$ 36.85	D	Â
Stock Option (Right to Buy)	Â ⁽³⁾	08/06/2023	Common Stock	18,000	\$ 22.55	D	Â
Stock Option (Right to Buy)	Â ⁽⁴⁾	01/10/2024	Common Stock	15,000	\$ 12.91	D	Â
Stock Option (Right to Buy)	Â ⁽⁵⁾	01/14/2025	Common Stock	31,095	\$ 15.74	D	Â
Stock Option (Right to Buy)	Â ⁽⁶⁾	01/06/2026	Common Stock	32,589	\$ 6.71	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Kutok Jeffery C/O INFINITY PHARMACEUTICALS, INC. 784 MEMORIAL DRIVE. CAMBRIDGE, MA 02139	Â	Â	Â Chief Scientific Officer	Â

Signatures

/s/Jeffery Kutok 02/14/2017

^{__}Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vested as to 12/48th of the shares on January 4, 2012 and vested as to 1/48th of the shares at the end of each calendar month thereafter. The option has fully vested.
 - (2) The option vested in equal monthly installments over four years beginning at the end of the calendar month during which the grant was made. The option has fully vested.
 - (3) The option vests as to 1/48th of the shares on August 31, 2013 and vests as to 1/48th of the shares at the end of each calendar month thereafter.

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 3

- (4) The option vests as to 1/48th of the shares on January 31, 2014 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
- (5) The option vests as to 1/48th of the shares on January 31, 2015 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
- (6) The option vests as to 1/48th of the shares on January 31, 2016 and vests as to 1/48th of the shares at the end of each calendar month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.